Sickle cell anemia (SCA) is the most common genetic disorder that is caused due to mutation of the ß globin gene. Although SCA is a monogenic disorder, the clinical presentation varies greatly among patients. The present study was designed to be a cross sectional study, aimed at analysing the SCA severity and its association with different clinical, biochemical and hematological variables in SCA patients of Indian origin. About 190 random homozygous SCA patients confirmed by hemoglobin electrophoresis were used in the study. Routine biochemical laboratory (liver function test and Renal function test) and hematologic tests (Total hemoglobin, fetal hemoglobin, hematocrit, MCV and MCH) were done. Values pertaining to complete blood count (CBC), Hb-HPLC and clinical investigations were collected from patient’s records. The mean age of patients with severe disease was significantly lesser than the moderate and mild disease patients. The body mass index (BMI) was also significantly lower in severe disease patients compared to the moderate and mild disease. The patients with severe disease had low levels of red blood cells, total hemoglobin (tHb) and fetal hemoglobin (HbF) compared to the other groups. There is no significant difference in the kidney and liver function among various degrees of disease severity. In summary, this study demonstrates that the tHb and HbF and total leucocyte count (TLC) are major prognostic factors for several clinical complications in SCA. Baseline measurement of these important variables is paramount in predicting important aspects of clinical course and improves the quality lives of these children.
Cite this article:
Bhaskar L.V.K.S., Smaranika Pattnaik. Association of Clinical and Hematological variables with the disease severity in Indian Sickle cell anemia patients. Research Journal of Pharmacy and Technology. 2021; 14(10):5254-7. doi: 10.52711/0974-360X.2021.00915
Bhaskar L.V.K.S., Smaranika Pattnaik. Association of Clinical and Hematological variables with the disease severity in Indian Sickle cell anemia patients. Research Journal of Pharmacy and Technology. 2021; 14(10):5254-7. doi: 10.52711/0974-360X.2021.00915 Available on: https://rjptonline.org/AbstractView.aspx?PID=2021-14-10-33
1. Bhaskar LVKS and Patra PK. Sickle cell disease is autochthonous and unique in Indian populations. Indian Journal of Physical Anthropology and Human Genetics 2015; 34: 201-210.
2. Caboot JB and Allen JL. Hypoxemia in sickle cell disease: significance and management. Paediatric respiratory reviews 2014; 15: 17-23.
3. Al-Mosawi RAS and Al-Fartosi KG. Oxidant and Antioxidant Status of patients with Sickle cell–ß Thalassemia in Thi-Qar Province, Iraq. Research Journal of Pharmacy and Technology 2020; 13: 4796-4800.
4. Li X, Dao M, Lykotrafitis G, et al. Biomechanics and biorheology of red blood cells in sickle cell anemia. J Biomech 2017; 50: 34-41.
5. Lakkakula B, Sahoo R, Verma H, et al. Pain Management Issues as Part of the Comprehensive Care of Patients with Sickle Cell Disease. Pain management nursing : official journal of the American Society of Pain Management Nurses 2018; 19: 558-572.
6. Vichinsky E. Chronic organ failure in adult sickle cell disease. Hematology American Society of Hematology Education Program 2017; 2017: 435-439.
7. Ahmad RI, Nassif ZB, Ismail ZM, et al. The Prevalence of gallstones in patients with Sickle cell anemia in Lattakia-Syria. Research Journal of Pharmacy and Technology 2020; 13: 3615-3617.
8. Kanter J and Kruse-Jarres R. Management of sickle cell disease from childhood through adulthood. Blood reviews 2013; 27: 279-287.
9. Bhaskar L. Genetic screening in sickle cell anemia. Polymorphism 2019; 3: 35-37.
10. Kumar R. Sickle Cell Anemia Introduction and Management. Research Journal of Pharmacology and Pharmacodynamics 2011; 3: 334-339.
11. van den Tweel XW, van der Lee JH, Heijboer H, et al. Development and validation of a pediatric severity index for sickle cell patients. American journal of hematology 2010; 85: 746-751.
12. Coelho A, Dias A, Morais A, et al. Sickle cell disease severity scoring: a yet unsolved problem. European journal of haematology 2012; 89: 501-502.
13. Thein SL. Molecular basis of β thalassemia and potential therapeutic targets. Blood Cells, Molecules, and Diseases 2018; 70: 54-65.
14. Sripichai O and Fucharoen S. Fetal hemoglobin regulation in β- thalassemia: heterogeneity, modifiers and therapeutic approaches. Expert review of hematology 2016; 9: 1129-1137.
15. Ahmad RI, Al-Barry HA and Salloum SI. Fetal Hemoglobin (HbF) levels in Sickle cell anemia patients in Lattakia, Syria. Research Journal of Pharmacy and Technology 2020; 6: 28.76-24.14.
16. Quinn CT. Minireview: Clinical severity in sickle cell disease: the challenges of definition and prognostication. Experimental biology and medicine (Maywood, NJ) 2016; 241: 679-688.
17. Jesus ACdSd, Konstantyner T, Lôbo IKV, et al. Características socioeconômicas e nutricionais de crianças e adolescentes com anemia falciforme: uma revisão sistemática. Revista Paulista de Pediatria 2018; 36: 491-499.
18. Shrivastava P, Bansal A and Kantharaj C. Incidence of Sickle Cell Disorder among Tribal and Non Tribal Community of Bastar (India). Research Journal of Science and Technology 2009; 1: 33-34.
19. Mohanty S, Sharma M, Dubey K, et al. Significance of Herbal Plants in the Treatment of Sickle Cell Anaemia. Research Journal of Pharmacy and Technology 2012; 5: 297-301.
20. Danladi BY and Geetha P. Ways to improve Life Expectancy in Sickle Cell Anaemia Patients using Herbs. Asian Journal of Research in Pharmaceutical Science 2017; 7, 205-208.
21. van den Tweel XW, van der Lee JH, Howard J, et al. Measurement of Disease Severity in Patients with Sickle Cell Disease: A Systematic Review. American Society of Hematology, 2007.
22. Henu Kumar V, Saikrishna L and Bhaskar VKSL. Retrospection of the effect of hydroxyurea treatment in patients with sickle cell disease. Acta Haematologica Polonica 2018; 49: 1-8.
23. McKerrell TD, Cohen HW and Billett HH. The older sickle cell patient. American journal of hematology 2004; 76: 101-106.
24. Losada R, Bravo I, Capildeo K, et al. Is the group of older sickle cell disease patients from Trinidad and Tobago different? American journal of hematology 2006; 81: 219-220.
25. Smith-Whitley K and Thompson AA. Indications and complications of transfusions in sickle cell disease. Pediatric blood & cancer 2012; 59: 358-364.
26. Blinder MA, Vekeman F, Trahey A, et al. Age-Related Blood Transfusion Patterns in Patients with Sickle Cell Disease (SCD) and the Association with Sickle Cell Complications. Blood 2011; 118: 12-12.
27. Koshy M, Entsuah R, Koranda A, et al. Leg ulcers in patients with sickle cell disease. Blood 1989; 74: 1403-1408.
28. Platt OS, Brambilla DJ, Rosse WF, et al. Mortality in sickle cell disease. Life expectancy and risk factors for early death. N Engl J Med 1994; 330: 1639-1644.
29. Lettre G, Sankaran VG, Bezerra MA, et al. DNA polymorphisms at the BCL11A, HBS1L-MYB, and beta-globin loci associate with fetal hemoglobin levels and pain crises in sickle cell disease. Proceedings of the National Academy of Sciences of the United States of America 2008; 105: 11869-11874.
30. Litos M, Sarris I, Bewley S, et al. White blood cell count as a predictor of the severity of sickle cell disease during pregnancy. European journal of obstetrics, gynecology, and reproductive biology 2007; 133: 169-172.
31. Naprawa JT, Bonsu BK, Goodman DG, et al. Serum biomarkers for identifying acute chest syndrome among patients who have sickle cell disease and present to the emergency department. Pediatrics 2005; 116: e420-425.
32. Liem RI, O'Gorman MR and Brown DL. Effect of red cell exchange transfusion on plasma levels of inflammatory mediators in sickle cell patients with acute chest syndrome. American journal of hematology 2004; 76: 19-25.
33. Curtis SA, Danda N, Etzion Z, et al. Elevated Steady State WBC and Platelet Counts Are Associated with Frequent Emergency Room Use in Adults with Sickle Cell Anemia. PloS one 2015; 10: e0133116.
34. Jabbar EAK, Maktoof AA and Jouda J. Evaluation of Metal levels and Physiological parameters in Sickle cell anemia and their comparison with Iron deficiency anemia. Research Journal of Pharmacy and Technology 2020; 17: 57.
35. Schweiger DJ. Red cell distribution width in sickle cell anemia. The American journal of medical technology 1981; 47: 231-233.
36. Webster P and Castro O. Red cell distribution width in sickle cell disease. Annals of Clinical & Laboratory Science 1986; 16: 274-277.
37. Roberts GT and EL Badawi SB. Red Blood Cell Distribution Width Index in Some Hematologic Diseases. American Journal of Clinical Pathology 1985; 83: 222-226.
38. Saha N and Samuel AP. Sickle cell gene and liver functions in a Sudanese population. Acta haematologica 1982; 68: 65-67.
39. Shah R, Taborda C and Chawla S. Acute and chronic hepatobiliary manifestations of sickle cell disease: A review. World J Gastrointest Pathophysiol 2017; 8: 108-116.
40. Aleem A. Renal abnormalities in patients with sickle cell disease: a single center report from Saudi Arabia. Saudi journal of kidney diseases and transplantation: an official publication of the Saudi Center for Organ Transplantation, Saudi Arabia 2008; 19: 194-199.
41. Lakkakula B, Verma HK, Choubey M, et al. Assessment of renal function in Indian patients with sickle cell disease. Saudi journal of kidney diseases and transplantation: an official publication of the Saudi Center for Organ Transplantation, Saudi Arabia 2017; 28: 524-531.
42. al-Naama LM, al-Sadoon EA and al-Sadoon TA. Levels of uric acid, urea and creatinine in Iraqi children with sickle cell disease. JPMA The Journal of the Pakistan Medical Association 2000; 50: 98-102